Hodgkin's Lymphoma

**Previously Untreated**

1. **BMT320**
   - Phase II: Very Low Dose Total Body Irradiation in Combination with Total Lymphoid Irradiation and anti-Thymocyte Globulin to Improve Donor Engraftment in Patients Undergoing Non-MHCT
   - PI: Muffy
   - Sponsor: Stanford

2. **VAR0174**
   - Leveraging Mindsets to Improve Health & Wellbeing in Patients with Cancer
   - PI: Crum
   - Stanford

3. **LYMH0015**
   - Pilot
   - Brentuximab
   - Vudotin + AVD Chemo & Involved-Site RT
   - Diagnosed Early Stage Hodgkin Lymph
   - PI: Advani
   - Memorial Sloan Kettering

4. **LYMH0016**
   - Phase II
   - Nivolumab & Brentuximab
   - Vudotin in Untreated HD Over age 60 or Unable to Receive ABVD Chemo
   - PI: Advani
   - Academic and Community Cancer Research United (ACCRU)

5. **LYMH0017**
   - Phase II
   - PET-Directed Frontline Tx w/ Pembrolizumab & AVD in Classical Hodgkin Lymphoma
   - PI: Advani
   - Sponsor: Northwestern University Medical School

**Previously Treated**

1. **MATCH Screening**
   - No mutation match
   - If matches (a) mutation(s) in 1 ≤ treatment arms

2. **ECOG-E4142**
   - Phase I+
   - Expansion
   - Ipilimumab & Brentuximab
   - Vudotin in Relapsed/Refractory Hodgkin Lymphoma
   - PI: Advani
   - ECOG-ACRIN

3. **ECOG-ACRIN-EAY131**
   - Molecular Analysis for Therapy Choice (MATCH)
   - PI: Ford
   - ECOG-ACRIN

**KEY**
- Pending
- Open for Enrollment
- Optional Path
- Link
- Trial Posting
- Extension Study
- Immunotherapy
- Enrollment on Hold